|
Dr. Kahl is an Assistant Professor of Medicine at the University of Wisconsin. He is the Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies for the University of Wisconsin Comprehensive Cancer Center. He received his medical degree from Tufts University where he was elected AOA. He completed all post-graduate training at the University of Wisconsin. Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.
Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of ECOG study E4402, Rituximab Extended Schedule or Retreatment Trial (RESORT) and ECOG study E1405, VcR-CVAD plus rituximab maintenance for Mantle Cell Lymphoma.
|
